title: Prognostic factors for patients with bone-only metastasis in breast cancer.
abstract: OBJECTIVE
  Bone is the most frequent site of metastasis among breast cancer patients. We investigated prognostic factors affecting survival following bone-only metastasis in breast cancer patients.
  
  
  METHODS
  The medical records of breast cancer patients who were treated and followed at Gangnam Severance Hospital retrospectively reviewed to identify patients with bone-only metastasis.
  
  
  RESULTS
  The median time from the diagnosis of bone-only metastasis to the last follow-up or death was 55.2 [95% confidence interval (CI), 38.6-71.9] months. The Kaplan-Meier overall survival estimate at 10 years for all patients was 34.9%. In the multivariate Cox regression model, bisphosphonate treatment [hazard ratio=0.18; 95% CI, 0.07-0.43], estrogen receptor positivity (hazard ratio=0.51; 95% CI, 0.28-0.94), and solitary bone metastasis (hazard ratio=0.32; 95% CI, 0.14-0.72) were significantly associated with longer overall survival in the bone-only recurrence group. Among the treatment modalities, only bisphosphonate treatment was identified as a significant prognostic factor.
  
  
  CONCLUSIONS
  Identifying the factors influencing breast cancer mortality after bone-only metastasis will help clarify the clinical course and improve the treatment outcome for patients with breast cancer and bone-only metastasis. Bisphosphonates, as a significant prognostic factor, warrant further investigation.
authors.affiliation: Department of Surgery, Gangnam Severance Hospital, Yonsei University Medical College, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea.
authors.forename: Sung Gwe
authors.initials: SG
authors.lastname: Ahn
authors.forename: Hak Min
authors.initials: HM
authors.lastname: Lee
authors.forename: Sang-Hoon
authors.initials: SH
authors.lastname: Cho
authors.forename: Seung Ah
authors.initials: SA
authors.lastname: Lee
authors.forename: Seung Hyun
authors.initials: SH
authors.lastname: Hwang
authors.forename: Joon
authors.initials: J
authors.lastname: Jeong
authors.forename: Hy-De
authors.initials: HD
authors.lastname: Lee
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D011960:Receptors, Estrogen / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D012044:Regression Analysis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
keywords: Breast neoplasm; bisphosphonate; bone metastses
references.citation: Ann Oncol. 2003 Aug;14(8):1234-40
references.pmid: 12881385
references.citation: Eur J Cancer. 2002 Sep;38(14):1860-70
references.pmid: 12204668
references.citation: Eur J Cancer. 2000 Mar;36(4):476-82
references.pmid: 10717523
references.citation: Cancer. 2003 Oct 15;98(8):1735-44
references.pmid: 14534891
references.citation: J Clin Oncol. 2003 Aug 15;21(16):3150-7
references.pmid: 12915606
references.citation: Br J Cancer. 2001 Apr 20;84(8):1126-34
references.pmid: 11308265
references.citation: Eur J Cancer. 2012 Jan;48(2):187-95
references.pmid: 22100904
references.citation: Tumour Biol. 2006;27(2):92-103
references.pmid: 16582586
references.citation: J Clin Oncol. 1998 Jun;16(6):2038-44
references.pmid: 9626201
references.citation: N Engl J Med. 1998 Oct 1;339(14):974-84
references.pmid: 9753714
references.citation: Oncologist. 2011;16(2):155-64
references.pmid: 21266401
references.citation: J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78
references.pmid: 18695136
references.citation: J Clin Oncol. 1988 Jan;6(1):89-97
references.pmid: 3275752
references.citation: Cancer. 2000 Mar 1;88(5):1082-90
references.pmid: 10699899
references.citation: J Clin Oncol. 1987 Jan;5(1):55-61
references.pmid: 3806159
references.citation: BMC Cancer. 2009 May 20;9:154
references.pmid: 19454038
references.citation: Br J Cancer. 1998;77(2):336-40
references.pmid: 9461007
references.citation: Cancer. 1986 Dec 15;58(12):2589-93
references.pmid: 3779609
references.citation: Lancet. 1984 Mar 17;1(8377):588-91
references.pmid: 6142305
references.citation: Cancer. 2000 Jul 15;89(2):363-8
references.pmid: 10918167
references.citation: Cancer J. 2001 Sep-Oct;7(5):377-87
references.pmid: 11693896
references.citation: Ann Oncol. 2008 Dec;19(12):2007-11
references.pmid: 18664560
references.citation: N Engl J Med. 2009 Feb 12;360(7):679-91
references.pmid: 19213681
references.citation: Acta Oncol. 2004;43(7):650-6
references.pmid: 15545185
references.citation: J Clin Oncol. 2000 Dec 1;18(23):3925-35
references.pmid: 11099322
references.citation: Ann Oncol. 2010 Nov;21(11):2188-2194
references.pmid: 20444845
references.citation: Cancer. 2004 Jan 1;100(1):36-43
references.pmid: 14692022
references.citation: J Clin Oncol. 1999 Mar;17(3):846-54
references.pmid: 10071275
references.citation: N Engl J Med. 1996 Dec 12;335(24):1785-91
references.pmid: 8965890
references.citation: Br J Cancer. 2003 Aug 18;89(4):660-5
references.pmid: 12915874
references.citation: Am J Med. 1986 Sep;81(3):381-6
references.pmid: 2428242
references.citation: Cancer. 2003 Feb 1;97(3):545-53
references.pmid: 12548595
references.citation: Clin Cancer Res. 2003 Aug 1;9(8):2893-7
references.pmid: 12912933
references.citation: Breast Cancer Res Treat. 2000 Feb;59(3):271-8
references.pmid: 10832597
references.citation: Cancer. 2012 Apr 15;118(8):2039-47
references.pmid: 22139648
references.citation: BMC Cancer. 2006 Jul 06;6:179
references.pmid: 16824210
references.citation: J Clin Oncol. 1996 Oct;14(10):2738-46
references.pmid: 8874335
references.citation: N Engl J Med. 2011 Oct 13;365(15):1396-405
references.pmid: 21995387